Zevra has obtained access to Acer’s rare disease assets Olpruva and Edsivo. Zevra Therapeutics has concluded its takeover of complete outstanding shares of Acer Therapeutics to form a rare disease company in a $91m deal. Zevra has obtained access to Acer’s rare...

    Alkermes plc, had announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company. Under the terms of the agreement, upon the closing of the...

  Rain Oncology Inc, had announced that it has entered into a definitive merger agreement whereby Pathos AI, Inc. will acquire Rain Oncology. Privately held Pathos AI, a company focused on leveraging machine learning and real-world data in drug development, will make a cash...

Bristol Myers Squibb had announced a definitive merger agreement under that it will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both...